ReviewInfectious diseases and therapy2016
Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.
Review in Infectious diseases and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.JAC-antimicrobial resistance · 2026Article
- Global burden of antimicrobial-resistant Staphylococcus aureus lower respiratory tract infections in older adults: a secondary analysis of the MICROBE database (1990-2021).BMC infectious diseases · 2026Article
- Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study.Pharmaceutics · 2026Article
- Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature.Antibiotics (Basel, Switzerland) · 2026Review
- Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use.Drugs in context · 2026Article
- Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report.Respiratory medicine case reports · 2026Article
- A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?Infectious diseases and therapy · 2025Review
- Periprosthetic joint infection after arthroplasty: advances and future prospects.Journal of orthopaedic surgery and research · 2025Review
- Natural peptides and their synthetic congeners acting againstRSC medicinal chemistry · 2025Review
- Rational construction of a high-quality and high-efficiency biosynthetic system and fermentation optimization for A82846B based on combinatorial strategies in Amycolatopsis orientalis.Microbial cell factories · 2024Article
- Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.ACS infectious diseases · 2024Review
- New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides.Pathogens (Basel, Switzerland) · 2024Review
- War and peace: exploring microbial defence systems as a source of new antimicrobial therapies.Frontiers in pharmacology · 2024Review
- Design methods for antimicrobial peptides with improved performance.Zoological research · 2023Review
- Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections.Open forum infectious diseases · 2023Article
- New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Kimyrsa and Orbactiv - A Tale of Two Formulations.Drug design, development and therapy · 2023Review
- Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.ACS infectious diseases · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Resistance among Gram-positive organisms has been steadily increasing over the last several years; however, the development of new antibiotics to treat infections caused from these organisms has fallen short of the emergent need. Specifically, resistance among Staphylococcus aureus and Enterococcus spp. to essential antibiotics is considered a major problem. Oritavancin is a semisynthetic lipoglycopeptide antibiotic that was recently approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). While structurally related to vancomycin, oritavancin also possesses unique mechanisms of action that greatly enhance its antimicrobial potency against multi-drug resistant pathogens including both VanA- and VanB-mediated vancomycin-resistant enterococci. Owing to the addition of the highly hydrophobic tail group, oritavancin possesses a prolonged half-life ranging from 200-300 h. Although oritavancin is only currently Food and Drug Administration approved for ABSSSI, this agent may eventually play a role in additional indications where new innovative therapy is needed including bacteremia and deep-seeded, Gram-positive infections such as infective endocarditis or osteomyelitis. This review will focus on oritavancin's spectrum of activity, mechanisms of action and resistance, pharmacokinetic and pharmacodynamic properties, and the completed and ongoing clinical studies evaluating its use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.